Children with HIV given cotrimoxazole prophylaxis along with antiretroviral therapy for at least 96 weeks and who continued receiving cotrimoxazole for another 96 weeks had reduced systemic inflammation compared with those who didn't receive the additional 96 weeks, researchers reported in Science Translational Medicine. AIDS-related adverse outcomes were more likely 48 weeks after discontinuing cotrimoxazole.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.